Project Solace

Did you know? Starting on January 5th, 2022, prescribers in Canada can now request psilocybin on behalf of their patients through Canada's Special Access Program!

TheraPsil's Project Solace aims to streamline access

via the Special Access Program

for patients and providers, and gather data on treatment outcomes.

What is Project Solace?

Project Solace is the world's largest medical psilocybin access and data project. This project aims to expand legal access to psilocybin for patients in medical need, while developing a substantial body of evidence, using a real-world data registry. The real world data registry will document clinical effectiveness, safety, and clinician and patient reported outcomes in patients who have received medical psilocybin-assisted psychotherapy via the Special Access Program.

Project Solace is beginning as a pilot project and will be open for patient and healthcare professional enrolment in the coming months. If you are a patient, healthcare professional or psilocybin manufacturer, please follow the instructions below:

If you are a patient in medical need of psilocybin : 

If you are a patient in medical need of psilocybin and would like to be notified when Project Solace is open for enrolment please join our waitlist by completing our patient intake form. You will find this form and more information on our Patient Page here. 

If you are a prescribing healthcare practitioner :

If you are a prescribing healthcare practitioner (MD or Nurse Practitioner) and you would like to refer a patient for psilocybin-assisted psychotherapy, please visit our Support your Patient page here.

Prescribers are encouraged to enroll in TheraPsil's 'Psilocybin Therapy Training Program'. Learn more and sign up by visiting our training page.

If you are a psilocybin Manufacturer  :

If you are a Psilocybin Manufacturer and you would like to learn more about Project Solace, please emailed our Director of Research, Julia Joyes at Julia@therapsil.ca.

F.A.Q.

Want to sign up for our Newsletter to stay in the loop?

Subscribe